Brief: Sionna Therapeutics Inc Maintains Strong Cash Position With About $310.3 Million In Cash And Cash Equivalents, Expected To Fund Operations Into 2028
02/03/2026 14:16
March 2 (Reuters) - Sionna Therapeutics Inc SION.O: SIONNA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS SIONNA THERAPEUTICS INC: MAINTAINS STRONG CASH POSITION WITH ABOUT $310.3 MILLION IN CASH AND CASH EQUIVALENTS, EXPECTED TO FUND OPERATIONS INTO 2028 Source text: ID:nGNX4ByJZX Further company coverage: SION.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sionna Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial
Sionna hits record low after experimental drug misses mid-stage trial goal
Vertex Pharma rises after rival genetic disorder drug setback